default author photo

Bruno Daniele

Azienda Ospedaliera G. Rummo

Benevento

Italy

SCHOLARLY PAPERS

2

DOWNLOADS

145

TOTAL CITATIONS

1

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients

Number of pages: 34 Posted: 10 Sep 2018
Giuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, Marica Eoli, Roberta Rudà, Marina Faedi, Ivan Lolli, Andrea Pace, Bruno Daniele, Francesco Pasqualetti, Simona Rizzato, Ardi Pambuku, Luisa Bellu, Miriam Farina, Giovanna Magni, Stefano Indraccolo, Marina Paola Gardiman and Vittorina Zagonel
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, University of Turin, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliera G. Rummo, Azienda Ospedaliera-Universitaria Pisana, Azienda Sanitaria-Universitaria Integrata, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), University of Padua - Padua General University Hospital and Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology
Downloads 76 (830,555)

Abstract:

Loading...

glioblastoma; regorafenib; lomustine; recurrent glioblastoma

2.

Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study

Number of pages: 35 Posted: 08 Feb 2020
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Arndt Vogel, Carlos López López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Corina E. Dutcus, Toshiyuki Tamai, Kenichi Saito and Riccardo Lencioni
Kindai University - Department of Gastroenterology and Hepatology, University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Nanjing Bayi Hospital, Yonsei University - Severance Hospital, Toranomon Hospital - Department of Hepatology, National Taiwan University - Department of Internal Medicine, University of Bologna, Kindai University - Faculty of Medicine, Hiroshima University - Hiroshima University Hospital, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hospital Marqués de Valdecilla, Comprehensive Cancer Center Eugène Marquis, Fudan University - Shanghai Cancer Center (FUSCC), Azienda Ospedaliera G. Rummo, National Cancer Center, Korea, Clatterbridge Cancer Centre, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc., Eisai, Inc. - Eisai, Inc. - United States and University of Miami - Miller School of Medicine
Downloads 69 (883,195)
Citation 1

Abstract:

Loading...

landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint